<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C03225F3-03C3-43C0-BE65-A8A629530193"><gtr:id>C03225F3-03C3-43C0-BE65-A8A629530193</gtr:id><gtr:name>University Medical Ctr Hamburg-Eppendorf</gtr:name><gtr:address><gtr:line1>Martinistrasse 52</gtr:line1><gtr:postCode>D-20246</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at North Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75"><gtr:id>082E3C1A-59C5-4E8A-BBC9-AB9D3571AE75</gtr:id><gtr:name>Sanford Burnham Medical Research Inst</gtr:name><gtr:address><gtr:line1>10901 North Torrey Pines Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C03225F3-03C3-43C0-BE65-A8A629530193"><gtr:id>C03225F3-03C3-43C0-BE65-A8A629530193</gtr:id><gtr:name>University Medical Ctr Hamburg-Eppendorf</gtr:name><gtr:address><gtr:line1>Martinistrasse 52</gtr:line1><gtr:postCode>D-20246</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/040001EB-7CD7-4B8C-998C-7097FA7B9B98"><gtr:id>040001EB-7CD7-4B8C-998C-7097FA7B9B98</gtr:id><gtr:name>Mount Sinai Hospital (Canada)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EEEF4B76-78C7-493E-9649-160C811E1F04"><gtr:id>EEEF4B76-78C7-493E-9649-160C811E1F04</gtr:id><gtr:firstName>Lindsay</gtr:firstName><gtr:otherNames>S</gtr:otherNames><gtr:surname>Keir</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901987"><gtr:id>FBDB15A3-06D4-4876-9499-6816E570A9FD</gtr:id><gtr:title>Understanding the pathogenesis of haemolytic uraemic syndrome: the role of the podocyte</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0901987</gtr:grantReference><gtr:abstractText>Haemolytic uraemic syndrome (HUS) is the leading cause of acute kidney failure in children. 1-5%
of children with HUS die and some are left with chronic kidney damage. It is commonly caused by a
gastrointestinal infection (E.coli) that affects &amp;gt;1000 people/year in Britain. It produces toxins, which
in 10-15% of cases causes kidney and other organ damage. It is a public health concern. Currently,
we do not understand how HUS is caused and therefore management focuses on supportive care.
Recent work by our collaborators using a mouse model has provided a potential breakthrough in our
understanding of HUS.
This project will build on this and aims to investigate the kidney effects of HUS. It will study the
effects of the toxin on specific kidney cells. We will create a mouse model that closely resembles the
disease in humans. This part of the project is underway. We will also look at human kidney cells
using different techniques to see how the toxin affects them and, in particular, how the toxin affects
the interaction between these cells. Understanding how this disease affects the kidney will identify
potential ways of treating this condition and alleviate the suffering of affected children and their
families.</gtr:abstractText><gtr:technicalSummary>Aims: To investigate the role of the podocyte in the renal pathogenesis of diarrhoea associated
haemolytic uraemic syndrome (D+HUS).
Hypothesis: The renal pathogenesis of D+HUS is caused by E.coli-0157 derived shigatoxin (stx)
binding to podocytes, via Gb3 receptors, and reducing VEGF-A secretion. This directly affects
glomerular endothelial cell function causing thrombotic microangiopathy (TMA).
Objectives/Design:
Both in vivo and in vitro techniques will be used. We will create a murine model of paediatric HUS.
There is no reliable HUS animal model due to species variations in Gb3 expression. Humans show
glomerular Gb3 expression while mice show tubular expression. To overcome this, a podocyte
specific inducible Gb3 expressing mouse will be created. Transgenic and wild type mice will be
injected with stx to induce HUS. Building on our preliminary in vitro work, we will investigate
changes to podocyte VEGF-A secretion in response to stx. We will investigate the effects of reduced
VEGF-A on glomerular endothelial cells (GEnC), in particular the glycocalyx and the effect this has
on complement factor H binding. We know this is affected in atypical (D-) HUS.
Methods:
1) In vivo: A construct, which has tetracycline tet-o-promoter linked to Gb3 synthase has been
developed to create an inducible podocyte-specific Gb3 expressing mouse. Cloned plasmids
will be injected into the single-cell embryo, transferred into pseudo-pregnant mice and
allowed to reach term. Breeding of tet-o-Gb3 mice with podocin-RtTA mice (already existing)
will create mice that, when given doxycycline, will express Gb3 on podocytes only. This
controls production of Gb3 synthase avoiding cellular toxicity. Thus, over-coming species
variation and creating a model of HUS. Transgenic and wild-type will have stx injected
inducing HUS. Mice will have daily biochemical tests. Kidneys will be examined histologically
(gross+EM). In situ hybridisation will assess Gb3 expression and VEGF-A production in HUS.
2) In vitro: Bristol is a leader in studying podocyte and GEn cell lines. Using this resource I will
investigate the effects of stx on these cells. Particularly looking for changes in podocyte
VEGF-A secretion that may change the endothelial glycocalyx or complement factor H
binding. This could link the pathogenesis of D+ and D- HUS. Improved disease understanding
may identify potential therapeutic targets to help treat HUS.
Opportunities: This project provides experience in in vivo mouse work and in vitro work on
immortalised cells lines. It will help explore an important area of paediatric nephrology whilst
providing a backdrop to learn transferable research skill</gtr:technicalSummary><gtr:fund><gtr:end>2013-08-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-08-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>199284</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Hamburg-Eppendorf</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Podocytes produce complement proteins</gtr:description><gtr:id>0E89CF45-CB92-4FF4-A48A-F066AACB051E</gtr:id><gtr:impact>Poster presentation at ASN 2014. This work is also being prepared for publication.</gtr:impact><gtr:outcomeId>546129ca905029.04639704-1</gtr:outcomeId><gtr:partnerContribution>Our German collaborators also found that human podocytes synthesize complement proteins but focused more activatory proteins such as C3.</gtr:partnerContribution><gtr:piContribution>Independently we made the observation that human podocyte synthesize and secrete complement proteins. I particularly focused on the protective proteins such as complement factor H and CD46.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sanford-Burnham Medical Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CRISPR/Cas sytem to induce CFH mutations in RPE cells</gtr:description><gtr:id>D485864D-9E02-4F00-B778-1A5F0510EE46</gtr:id><gtr:impact>Nil yet. New cell line being developed</gtr:impact><gtr:outcomeId>546120321f06c7.92866151-1</gtr:outcomeId><gtr:partnerContribution>The stem cell core team carried out the cellular transfections of the CRISPR/Cas constructs and propagated the cells.</gtr:partnerContribution><gtr:piContribution>I designed the primers to sequence the CFH gene and we worked together to design the CFH construct to be introduced into the new cell line.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Complement proteins expression by human podocytes</gtr:description><gtr:id>891607B8-A558-41CC-9BD7-F362F2A3893B</gtr:id><gtr:impact>Separate posters presented at ASN, IPNA meetings Working towards joint publcations.</gtr:impact><gtr:outcomeId>LFoSSBJVuBv-1</gtr:outcomeId><gtr:partnerContribution>I carried out work on human podocytes to study the way they express protective complement regulators and have assessed this functionally. 
The collaborators have looked a the same cells but focused on their synthesis of activating complement proteins. 
The work is being combined for publication. I am writing the paper</gtr:partnerContribution><gtr:piContribution>New research collaboration. Both groups were working separately to study the expression of complement proteins in human podocytes. This was noted during a poster presented at the International Paedaitric Nephrology Association in China. The decision was made to combine these studies for publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Life Sciences</gtr:department><gtr:description>Shiga toxin Assay</gtr:description><gtr:id>6094614C-50E1-4BE5-AF50-DEE5446A205A</gtr:id><gtr:impact>This collaboration has provided me with the chance to carry out techniques which are not available yet at my insitution. However, with the help and knowledge shared in this colaboration I am now in a position to set up techniques at my host insitution.
Poster presentation Philadelphia American Society of Nephrology meeting Nov 2011
Oral presentation at the Academic Paediatric Association of Great Britain and Ireland-prize for the best scientific presentation awarded.
Oral presentation at Royal College of Paediatric and child health meeting, Glasgow May 2012. Award prize for best oral presentation.</gtr:impact><gtr:outcomeId>N48pfsviW9j-1</gtr:outcomeId><gtr:partnerContribution>Provided advice and practicle help to carry out shiga toxin experiments on glomerular conditionaly immortalised cells. Protocols were shared. Also suplied advice on toxin purification and reagents to use.</gtr:partnerContribution><gtr:piContribution>I visited the University of Warwick and carried out experiments on my cells with the help of the team. I initially contacted the Warwick team based on their extensive experience in this area.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scripps Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>The relationship between VEGF-A and complement regulator expression in the eye</gtr:description><gtr:id>253480E9-D58A-4364-B11A-34415C94467F</gtr:id><gtr:impact>Walls Bursary award from Renal Association-personal award
University of Bristol MRC Centenary award-personal award with consumables.
Lowy Medial Research Institute grant</gtr:impact><gtr:outcomeId>NwiGqNe3faK-1</gtr:outcomeId><gtr:partnerContribution>Collaborators provided human, mouse and rat tissue and cells for this project. I am contributing to the project with complement knowledge, assays and reagents. We are working together to create a new iPS RPE cell line from patients with factor H polymorphisms</gtr:partnerContribution><gtr:piContribution>Visit to the lab in California in 2012. Immunofluorescent staining carried out for complement regulators in mice and human tissue sections and cells. This pilot data was used to apply for a one year University of Bristol MRC Centenary award. This application was successful and I have spent one year at Scripps further exploring the role of complement regulators in the normal eye and in the disease Age related macular degeneration. This has results in presentation at ARVO and the Gordons Research conference in endothelial cell phenotypes in health and disease.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mount Sinai Hospital (Canada)</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Samuel Lunenfeld Research Institute</gtr:department><gtr:description>Mouse model of glomerular disease-pod1</gtr:description><gtr:id>30FB15FD-CE93-49CF-8447-01ABAC4DDA6B</gtr:id><gtr:impact>New techniques have been developed by myself which I hope to take back to my host insitution.
3 poster presentations: Great Lakes conference, Ontario, April 2012, Gordons Research Conference, Italy August 2012, American Society of Nephrology meeting San Diego, November 2012
2013, ASN, Atlanta November. Poster presentation. 
Prepared for submission to Journal of the American Society of Nephrology (JASN): expected submission end october 2013</gtr:impact><gtr:outcomeId>R8pfoYW5fh3-1</gtr:outcomeId><gtr:partnerContribution>Experience and knowledge on mouse models and techniques associated. Colony management, genotyping and a battery of techniques to study the phenotypes of the mice generated.</gtr:partnerContribution><gtr:piContribution>Working with the team has allowed me to share ideas and discuss projects. I have worked on a different project separate to my MRC funded project. This allowed me to gain hands on experience in a new field.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen's Medical Research Institute Edinburgh</gtr:department><gtr:description>Complement regulator study</gtr:description><gtr:id>3059CDFA-6FFA-4B1D-ACAF-A6FF86D27436</gtr:id><gtr:impact>Change in direction of the research at my host insitution. 
Poser presentation ASN, Philadelphia Nov 2011and at ASN San Diego Nov 2012
Oral Presentation at the Academic Paediatric Association of Great Britain and Ireland-Prize for best Scientific Presentation.
Poster presentation at Gordons Research Conference, Tuscany, August 2012.
Oral Presentation at European Society of Pediatric Nephrology (ESPN), September 2012-awarded BAPN travel award to attend.
Work presented by oral talk to pediatric nephrology research meeting Boston Childrens Hospital
Paper prepared for publication: planned submission winter 2013</gtr:impact><gtr:outcomeId>eBHf8hsvaQf-1</gtr:outcomeId><gtr:partnerContribution>Shared knowledge and advice on experimental design and data interpretation. The direction of the research has been guided through frequent meetings and discussion.</gtr:partnerContribution><gtr:piContribution>Frequent meetings to share data and discuss and analyse results have help to shape the direction of the research. Together we are sharing different experiences and expertise to look at things from a new angle.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Stx HUS working group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D1B80FC1-5711-44A0-94F4-DE9BCFD235D1</gtr:id><gtr:impact>HUSH patient group were approached to join in the Stx HUS working group and in turn we were asked to help update their patient/parent advice leaflets.

Provide closer links with health care professionals and patients and parents. Ensure that accurate up to date information is available to patients and parents.</gtr:impact><gtr:outcomeId>cFmpW798fS3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Mangotsfield)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AA1475D4-D972-4392-97F1-C5172CA425B6</gtr:id><gtr:impact>5 groups of 20 childrens aged 11-15yrs attended session about The kidney. Three practical activities were devised to teach them about the normal role of the kidney in humans and what happens in childhood diseases. They all had to write down questions during the session and some were chosen to ask these questions at the end.

Positive feedback from the children and science teachers. Plans to repeat the experience in future years.</gtr:impact><gtr:outcomeId>AWeAQVmJs8x</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.bristol.ac.uk/news/2013/9471.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary pop up science festival M Shed (University of Bristol)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>24028771-357D-4BD7-8EF6-30048A4ABA92</gtr:id><gtr:impact>Local people were invited to attend the M shed museum for a pop up science festival. MRC funded reseachers attended and presented their work to the public to illustrate their research. Small group sessions could be selected by the public to hear about a specific research area. I ran one of these and explained how eating undercooked meat can lead to Shiga toxin E.coli infections which can cause haemolytic uraemic syndrome and kidney injury.

Positive feedback obtained. Stronger relationship with the public engagement office. Will participate in such events in the future.</gtr:impact><gtr:outcomeId>bUbh7mPr7rU</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bristol.ac.uk/news/2013/9471.html</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kids Kidney Research UK</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7A07DEF9-1FBB-42AA-BA02-379C8B551BB7</gtr:id><gtr:impact>My supervisor Professor Saleem had received a start up grant from Kids Kidney UK which led to generation of preliminary data which helped to fund my project. As such they wanted to publise our work. Prof Saleem was asked to write a short script detailsing our project which could be understood by teenagers and children. I wrote this script. The charity now plans to record the script and put it on the internet to help tell children and thier families about the disease and the research we are carrying out.

Our project will be publised to children and their families who have an interest in kidney diseases.</gtr:impact><gtr:outcomeId>tRNmnUTjE3E</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Parent/Patient information (infoKid HUS)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BF9E1C2B-24B0-4FF4-8FB8-8DBF6C4E2A37</gtr:id><gtr:impact>This online resource is designed to disseminate information about Shiga toxin HUS to parents and patients and other members of the public.

Good feedback was received from the parent/patient group HUSH.</gtr:impact><gtr:outcomeId>546134b6e13b12.49455191</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.infokid.org.uk/STEC-HUS</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Clinican information (HUS)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41C29428-641C-4AD8-A05D-FFBD756B7ED3</gtr:id><gtr:impact>Clinician information on how to diagnose, manage and treat Shiga toxin HUS. It is hope that this will standardize care in this patient group.

Positive feedback from colleagues.</gtr:impact><gtr:outcomeId>546133555b0d78.92922559</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://rarerenal.org/clinician-information/haemolytic-uraemic-syndrome-clinician-information/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Association of Paediatric Nephrology travel award</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>British Association?for Paediatric Nephrology?(BAPN)</gtr:fundingOrg><gtr:id>8F88D8E2-CB9C-4FE1-A289-A63271611882</gtr:id><gtr:outcomeId>PBaa2f3dtjw</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>160000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Clinical Lecturer</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1EB46428-9721-48CA-A963-28EAF3FC4E4F</gtr:id><gtr:outcomeId>54612f1272fc00.43920289</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Walls Bursary</gtr:description><gtr:end>2012-11-02</gtr:end><gtr:fundingOrg>Renal Association</gtr:fundingOrg><gtr:id>DB1935EF-4951-4252-A0C6-946C70ABDE95</gtr:id><gtr:outcomeId>KkDdPruG2jr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Bristol MRC Centenary award</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>University of Bristol</gtr:fundingOrg><gtr:id>ECD88791-EC18-42D9-AACD-8B2A64181DD6</gtr:id><gtr:outcomeId>nzGPBmZPSUy</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A new transgenic mouse line was created. A construct was made linking a tet-o promoter to the gb3 synthase gene. This was microinjected into the pronuclei of a mouse. The resultant offspring were screened for construct insertion. 5 founder lines were established and each are not being tested for expression of Gb3 synthase and its product Gb3. The tet-o Gb3 synthase mice have been bred with podocin Rtta mice to create a glomerular podocyte specific Gb3 synthase expression. It has confirmed podocyte Gb3 expression after 10 days doxycycline induction. It has been tested with Shiga toxin and preliminary results show that mutant mice do have a glomerular phenotype.</gtr:description><gtr:id>CDBBD7C0-3DF1-4942-90FD-766706177110</gtr:id><gtr:impact>This model is still being testing. Preliminary results that these mice do develop a glomerular pheontype and so this could serve as a murine model for stx HUS, the most common cause of acute kidney failure in children. However, further investigation is required to work up its phenotype. Rescue experiments are also planned to test possible treatmnt options.</gtr:impact><gtr:outcomeId>ockpRiiLmy5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Podocyte specific Gb3 synthase expressing mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new conditionally immortalised mouse podocye cell line was created. This was characterised and then used for transfection with Gb3 synthase. The result was that the mouse podocytes express the cell receptor Gb3 which is not normally expressed by mouse podocytes.</gtr:description><gtr:id>C31335A1-C02F-427D-B71C-C042FDBBF0E9</gtr:id><gtr:impact>This work is still in its infancy but by transfecting the mouse podocytes with Gb3 we hope to study them with our shiga toxin assay. This was a preliminary experiment to se if our Gb3 synthase construct would produce Gb3. We are now using this gene with the RtTa/tet-o system to create a podocyte specific Gb3 synthase expressing mouse.</gtr:impact><gtr:outcomeId>AEcwDPNhSrU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Gb3 mouse podocyte expression</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A new assay was developed to functionally assess complement activation on cells in culture. Previously similar assays looked at cells in single cell suspension but glomerular endothelial cells do not normally exist in this way. Therefore the assay was adapted to allow cells to be studied whilst still in monolayer. IF was used to look for C3d and C4d deposits on the cell surface. Image J was then used to analyse and quantify the images obtained. Numerous control samples were also run alongside.</gtr:description><gtr:id>125D8D1E-25C7-4DFC-90CC-FD4F72EF062C</gtr:id><gtr:impact>This assay has allowed us to study glomerular endothelial cells in vitro and their response to complement. It has allowed us to study the effects of treatment on these cells and how they respond to complement. This work has been prepared for publication.</gtr:impact><gtr:outcomeId>ouMBeR3cqCA</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Immunofluorescent complement challenge assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>33D16FB3-A123-40C2-957A-736292DF4F10</gtr:id><gtr:title>Understanding the renal pathogenesis of diarrhoea associated haemolytic uraemic syndrome : the role of the podocyte</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe3ad5c7df2a50d8325396c3c690085b"><gtr:id>fe3ad5c7df2a50d8325396c3c690085b</gtr:id><gtr:otherNames>Keir Lindsay Susan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54611da5957286.39722667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6FD296E-CB0A-4D5D-A24C-DF7162D85E84</gtr:id><gtr:title>Generating conditionally immortalised podocyte cell lines from wild-type mice.</gtr:title><gtr:parentPublicationTitle>Nephron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1c1ce1e3361cf7210c0858e347d1ea2"><gtr:id>a1c1ce1e3361cf7210c0858e347d1ea2</gtr:id><gtr:otherNames>Keir LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1660-8151</gtr:issn><gtr:outcomeId>doi_55f98598542bc294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>233538BF-AB0D-49E8-B474-E2AF9DC423D0</gtr:id><gtr:title>Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1c1ce1e3361cf7210c0858e347d1ea2"><gtr:id>a1c1ce1e3361cf7210c0858e347d1ea2</gtr:id><gtr:otherNames>Keir LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>pm_14209_29_23843163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD125E61-9592-4D19-95EC-F4186D6626E9</gtr:id><gtr:title>Beware renal adverse effects of anti-vascular endothelial growth factor treatment.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0c849e4a8953a08a1521f76110607a"><gtr:id>ec0c849e4a8953a08a1521f76110607a</gtr:id><gtr:otherNames>Keir L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_14209_29_22661730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BAFDEAC-7BB2-4364-86B6-5B828D11DBB4</gtr:id><gtr:title>Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.</gtr:title><gtr:parentPublicationTitle>Drug design, development and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1c1ce1e3361cf7210c0858e347d1ea2"><gtr:id>a1c1ce1e3361cf7210c0858e347d1ea2</gtr:id><gtr:otherNames>Keir LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1177-8881</gtr:issn><gtr:outcomeId>pm_14209_29_22888220</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04F0E3A9-5E39-45F6-8FCC-91591624B7A4</gtr:id><gtr:title>Loss of the podocyte-expressed transcription factor Tcf21/Pod1 results in podocyte differentiation defects and FSGS.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b078ad00bb8d5e82f11a15cd5125ec13"><gtr:id>b078ad00bb8d5e82f11a15cd5125ec13</gtr:id><gtr:otherNames>Maezawa Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>54611cd9cc1873.25529489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA30C86C-0D12-427D-80FC-C8DFD3FD4338</gtr:id><gtr:title>Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy.</gtr:title><gtr:parentPublicationTitle>Pediatric nephrology (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec0c849e4a8953a08a1521f76110607a"><gtr:id>ec0c849e4a8953a08a1521f76110607a</gtr:id><gtr:otherNames>Keir L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0931-041X</gtr:issn><gtr:outcomeId>pm_14209_29_20949284</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901987</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>